BioXcel Financial Statements (BTAI)
|
|
|
|
Report date
|
|
|
16.03.2023 |
01.05.2023 |
22.03.2024 |
28.03.2025 |
27.03.2026 |
|
27.03.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
0.375 |
0.375 |
1.38 |
2.27 |
0.642 |
|
0.642 |
|
Operating Income, bln rub |
|
|
-159.6 |
-159.6 |
-171.8 |
-67.2 |
-49.7 |
|
-50.1 |
|
EBITDA, bln rub |
? |
|
-157.2 |
-157.4 |
-165.4 |
-44.2 |
-49.4 |
|
-54.6 |
|
Net profit, bln rub |
? |
|
-165.8 |
-171.8 |
-179.1 |
-59.6 |
-69.9 |
|
-69.9 |
|
|
OCF, bln rub |
? |
|
-135.3 |
-135.3 |
-155.0 |
-72.0 |
-57.6 |
|
-57.6 |
|
CAPEX, bln rub |
? |
|
0.139 |
0.139 |
0.020 |
0.000 |
0.000 |
|
0.000 |
|
FCF, bln rub |
? |
|
-135.5 |
-135.5 |
-155.0 |
-72.0 |
-57.6 |
|
-57.6 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
160.0 |
160.0 |
171.9 |
67.4 |
49.9 |
|
50.4 |
|
Cost of production, bln rub |
|
|
0.020 |
0.020 |
1.26 |
2.14 |
0.464 |
|
0.313 |
|
R&D, bln rub |
|
|
91.2 |
91.2 |
84.3 |
30.4 |
30.3 |
|
29.9 |
|
Interest expenses, bln rub |
|
|
8.21 |
8.21 |
13.3 |
15.1 |
17.0 |
|
13.0 |
|
|
Assets, bln rub |
|
|
205.9 |
205.9 |
73.7 |
38.3 |
44.9 |
|
44.9 |
|
Net Assets, bln rub |
? |
|
76.8 |
76.8 |
-56.5 |
-93.1 |
-95.5 |
|
-95.5 |
|
Debt, bln rub |
|
|
94.2 |
94.2 |
101.4 |
102.9 |
109.6 |
|
109.6 |
|
Cash, bln rub |
|
|
193.7 |
193.7 |
65.2 |
29.9 |
28.4 |
|
28.4 |
|
Net debt, bln rub |
|
|
-99.6 |
-99.6 |
36.2 |
73.1 |
81.2 |
|
81.2 |
|
|
Ordinary share price, rub |
|
|
21.5 |
21.5 |
2.95 |
5.98 |
1.60 |
|
1.21 |
|
Number of ordinary shares, mln |
|
|
1.75 |
28.0 |
1.82 |
2.54 |
12.2 |
|
12.2 |
|
|
Market cap, bln rub |
|
|
38 |
602 |
5 |
15 |
20 |
|
15 |
|
EV, bln rub |
? |
|
-62 |
502 |
42 |
88 |
101 |
|
96 |
|
Book value, bln rub |
|
|
77 |
77 |
-57 |
-93 |
-95 |
|
-95 |
|
|
EPS, rub |
? |
|
-94.7 |
-6.13 |
-98.4 |
-23.5 |
-5.73 |
|
-5.73 |
|
FCF/share, rub |
|
|
-77.4 |
-4.84 |
-85.2 |
-28.4 |
-4.72 |
|
-4.72 |
|
BV/share, rub |
|
|
43.8 |
2.74 |
-31.0 |
-36.7 |
-7.82 |
|
-7.82 |
|
|
EBITDA margin, % |
? |
|
-41 925% |
-41 969% |
-11 987% |
-1 949% |
-7 695% |
|
-8 511% |
|
Net margin, % |
? |
|
-44 202% |
-45 826% |
-12 975% |
-2 630% |
-10 887% |
|
-10 887% |
|
FCF yield, % |
? |
|
-360.2% |
-22.5% |
-2 887% |
-475.1% |
-295.0% |
|
-390.0% |
|
ROE, % |
? |
|
-215.9% |
-223.8% |
316.9% |
64.0% |
73.2% |
|
73.2% |
|
ROA, % |
? |
|
-80.5% |
-83.5% |
-242.9% |
-155.5% |
-155.6% |
|
-155.6% |
|
|
P/E |
? |
|
-0.23 |
-3.50 |
-0.03 |
-0.25 |
-0.28 |
|
-0.21 |
|
P/FCF |
|
|
-0.28 |
-4.44 |
-0.03 |
-0.21 |
-0.34 |
|
-0.26 |
|
P/S |
? |
|
100.3 |
1 605 |
3.89 |
6.69 |
30.4 |
|
23.0 |
|
P/BV |
? |
|
0.49 |
7.84 |
-0.10 |
-0.16 |
-0.20 |
|
-0.15 |
|
EV/EBITDA |
? |
|
0.39 |
-3.19 |
-0.25 |
-2.00 |
-2.04 |
|
-1.76 |
|
Debt/EBITDA |
|
|
0.63 |
0.63 |
-0.22 |
-1.66 |
-1.64 |
|
-1.49 |
|
|
R&D/CAPEX, % |
|
|
65 640% |
65 640% |
421 630% |
|
|
|
|
|
|
CAPEX/Revenue, % |
|
|
37.1% |
37.1% |
1.45% |
0.00% |
0.00% |
|
0 |
|
| BioXcel shareholders |
